Founder says Panasci winner could be "a rapid growth biotech company"

PhotoZyne will seek expanded laboratory space in Buffalo – possibly at one of the facilities on the Buffalo Niagara Medical Campus – as it continues research and development into technology that aims to deliver cancer therapies without the severe effects of chemotherapy. The company will simultaneously pursue federal grants in the Small Tech Transfer Research program, which includes a phase one award of $225,000 and a phase two award of $1.5 million. “It’s a platform technology, so it has…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

Publication date: Available online 21 March 2019Source: European Polymer JournalAuthor(s): Aliyeh Ghamkhari, Farideh Mahmoodzadeh, Marjan Ghorbani, Hamed HamishehkarAbstractGold nanoparticles have been used for centuries in medicine for clinical procedures. In this context, gold nanorods are considered as very promising in cancer therapy. For this purpose, gold nanorods (GNRs) coated by stimuli-responsive thiol-end capped ABC triblock copolymer [poly (metacrylic acid)-block-poly (N-isopropylacrylamide)-block-poly (N,N-dimethylaminoethyl methacrylate)-SH; P(MAAc-b-NiPAAM-b-DMAEMA)-SH] for intracellular delivery of doxorubic...
Source: European Polymer Journal - Category: Chemistry Source Type: research
This study investigated the impact of immune-related pathway inhibition, among them indolamine 2,3-dioxygenase (IDO), alone and together with immune cells on growth and viability of colorectal cancer (CRC) cells. A panel of patient-derived CRC cell lines with different molecular characteristics (CpG island methylator phenotype, chromosomal, and microsatellite instability) was included. Initial phenotyping of CRC cell lines (n=17) revealed high abundance of immunosuppressive checkpoint-molecules in general, but an individual profile for IDO. Presence of immune-related molecules was independent of the molecular subtype. Sele...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
fellner Antibody-drug conjugates (ADCs) combine the tumor selectivity of antibodies with the potency of cytotoxic small molecules thereby constituting antibody-mediated chemotherapy. As this inherently limits the adverse effects of the chemotherapeutic, such approaches are heavily pursued by pharma and biotech companies and have resulted in four FDA (Food and Drug Administration)-approved ADCs. However, as with other cancer therapies, durable responses are limited by the fact that under cell stress exerted by these drugs, tumors can acquire mechanisms of escape. Resistance can develop against the antibody component of ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Abstract: Genomic analyses in oncologic care allow for the development of more precise clinical laboratory tests that will be critical for personalized pharmacotherapy. Traditional biopsy-based approaches are limited by the availability of sequential tissue specimens to detect resistance. Blood-based genomic profiling (“liquid biopsy”) is useful for longitudinal monitoring of tumor genomes and can complement biopsies. Tumor-associated mutations can be identified in cell-free tumor DNA (ctDNA) from patient blood samples and used for monitoring disease activity. The US Food and Drug Administration approved a li...
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Review Articles: Focus on Pharmacodynamic Drug Monitoring Source Type: research
Authors: Buck E, Sprick M, Gaida MM, Grüllich C, Weber TF, Herpel E, Bruckner T, Koschny R Abstract Recently, a tumor-autonomous cytochrome P450 (CYP)-3A5-mediated resistance to cancer therapy has been demonstrated in pancreatic ductal adenocarcinoma. Expression of CYP3A5, which is involved in the degradation of irinotecan, has also been reported in colorectal cancer (CRC). The aim of the present study was to analyze CYP3A5 expression in the normal colon, colon adenoma, CRC and normal tissues, as well as to examine whether CYP3A5 expression in CRC has an impact on tumor response to irinotecan treatment. Immuno...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
ConclusionThe combined regimen of the proteasome inhibitor delanzomib with Dox chemotherapy may become an effective strategy for breast cancer therapy.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Authors: Li Y, Zhang X, Yang X, Liu J, Li L, Ma W, Chen M Abstract Liver cancer is a major healthcare problem and one of the leading causes of cancer-associated mortality in the world. To date, chemotherapy remains a common method for treating cancer and cisplatin is one of the most widely used chemotherapeutics. However, owing to drug resistance and side effects, it is imperative to identify a novel approach to improve the anticancer effect of cisplatin. Auxiliary chemotherapy drugs with minor toxicity to normal cells may represent a novel strategy for cancer therapy. Previous studies have indicated that ginkgol C...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Conclusion: Nail changes, skin changes, hair changes and mucosal changes occurred frequently as a significant side effect of chemotherapy, which a physician should be aware of, while selecting a chemotherapeutic drug.
Source: Indian Journal of Dermatology - Category: Dermatology Authors: Source Type: research
Opinion statementBisphosphonates are utilized routinely in breast cancer. In metastatic disease with bone involvement, bisphosphonates prevent or delay skeletal-related events and can improve pain control. Different agents have shown benefit compared with placebo or no treatment. While in unselected patients, comparison between zoledronic acid and pamidronate did not show a significant difference, exploratory analyses showed that in patients with osteolytic lesions or hypercalcemia, zoledronic acid is superior to pamidronate. De-escalating treatment with zoledronic acid from every 4 to every 12  weeks has been shown t...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 12 March 2019Source: Biosensors and BioelectronicsAuthor(s): Nandini Dhiman, Peter Kingshott, Huseyin Sumer, Chandra S. Sharma, Subha Narayan RathAbstractThere is an increasing need for advanced and inexpensive preclinical models to accelerate the development of anticancer drugs. While costly animal models fail to predict human clinical outcomes, in vitro models such as microfluidic chips (‘tumor-on-chip’) are showing tremendous promise at predicting and providing meaningful preclinical drug screening outcomes. Research on ‘tumor-on-chips’ has grown enormously worl...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Grants | Health | Health Management | Laboratory Medicine